Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists
This Viewpoint discusses supply and demand for glucagon-like peptide 1 (GLP-1) receptor agonists and concerns with using compounded drugs to fill this demand.
Related Articles
Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease, 2020 to 2050
This decision analytical modeling study estimates the burden of metabolic dysfunction–associated steatotic liver disease among US adults from 2020 to 2050.
Neurological post-COVID syndrome is associated with substantial impairment of verbal short-term and working memory
Scientific Reports – Neurological post-COVID syndrome is associated with substantial impairment of verbal short-term and working memory
Trust in Physicians and Hospitals During the COVID-19 Pandemic
This survey study examines changes in US adults’ trust in physicians and hospitals over the course of the COVID-19 pandemic and the association between this…
‘No Cause for Panic’ as Sperm Counts Found To Be Steady
Several high-profile papers had suggested that sperm counts have drastically fallen globally over the past few decades. In contrast, new data from Cleveland Clinic suggest…
Odds of Opioid Misuse Lower in States With Medical Cannabis Laws
THURSDAY, Jan. 16, 2025 (HealthDay News) — For individuals reporting cannabis use, the odds of opioid misuse are reduced among individuals in states with medic
Preterm Birth and Caregiver Employment
This survey study compares employment decisions among caregivers of preterm infants during the first 3 years of an infant’s life by gestational age and birth…
Palmar Fasciitis and Polyarthritis Syndrome
This case report describes a man in his 50s with palmar fasciitis and polyarthritis syndrome.
Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial
Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial’s primary endpoint.
It May Be Easier to Quit Smoking With Holistic or Integrated Health Approach
TUESDAY, Jan. 14, 2025 (HealthDay News) — It takes a village to help a smoker quit.And a new study published recently in JAMA Internal Medicine…
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Eli Lilly’s CEO says the company is considering offering more Zepbound doses in vials at lower cost.
